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Abstract
Introduction Invasive fungal infections (IFIs) occur mostly in immunosuppressed patients and can be life-threatening.
Inadequate treatment is associated with high morbidity and mortality. We examined the role of 2-fluorodeoxyglucose positron
emission tomography integrated with CT (FDG-PET/CT) in monitoring IFIs and therapy decision-making, and evaluated the role
of baseline metabolic parameters in predicting the metabolic response.
Methods All patients between October 2009 and March 2018, diagnosed with IFIs, treated with antifungal drugs, and who
underwent FDG-PET/CT at baseline and at one or more timepoints during treatment were retrospectively included. The elec-
tronic patient files were reviewed for pathology, microbiology, and laboratory findings. All FDG-PET/CT scans were performed
according to standardized European Association of Nuclear Medicine/EANM Research Limited (EANM/EARL) protocols. For
each scan, the global total lesion glycolysis (TLG) and metabolic volume (MV), highest maximum standardized uptake value
(SUVmax), and peak standardized uptake value (SUVpeak) were determined. The role of FDG-PET/CT on monitoring antifun-
gal therapy was assessed by looking at the clinical decision made as result of the scan. Furthermore, the added value of the
baseline metabolic parameters in predicting metabolic response to the antifungal treatment was evaluated.
Results Twenty-eight patients with in total 98 FDG-PET/CT scans were included with a mean age of 43 ± 22 years. FDG-PET/
CT altered management in 14 out of the 28 patients (50%). At the final FDG-PET/CT scan, 19 (68%) had a complete metabolic
response (CMR), seven a partial response and two patients were defined as having progressive disease. Using receiver operative
analysis, the cut-off value, sensitivity, specificity, and significance for the baseline TLG and MV to discriminate patients with
CMR were 160, 94%, 100%, p < 0.001 and 60, 84%, 75%, p = 0.001 respectively.
Conclusion FDG-PET/CT is useful in the monitoring of IFIs resulting in management therapy change in half of the patients.
Baseline TLG and MV were found to be able to predict the metabolic response to antifungal treatment.
Keywords Invasive fungal infections . Therapy monitoring . Metabolic parameters . FDG-PET/CT . Total lesion glycolysis .
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Introduction
Invasive fungal infections (IFIs) often occur in immunosup-
pressed patients and can be life-threatening. Timely monitor-
ing of the efficacy of antifungal drugs in patients with IFIs is
crucial. There are only a few classes of antifungals available,
and it is crucial to preserve the effectiveness of these agents
[1]. Antifungal drugs are costly and frequently accompanied
by severe and sometimes intolerable side-effects. Patients with
IFIs are usually treated for extensive periods (months to some-
times even years), and the duration of treatment is not stan-
dardized. Inappropriate treatment with antifungal agents may
potentially result in potential fungal disease and can induce
resistant fungi, which increase morbidity or mortality [1–3].
Morbidity and mortality for IFIs vary considerably depending
on the type of IFI and underlying disease predisposing to IFI
[4, 5]. The mortality rates for the most common organisms
causing IFIs are usually about 30% [5]. Inadequate treatment
of IFIs may result in dissemination of the infection during
immunosuppressive procedures such as intensive chemother-
apy or stem-cell transplantation that are often used to treat
underlying conditions associated with IFIs. It is therefore crit-
ical to determine in a timely manner whether the antifungal
treatment regimen is adequate or whether modification of ther-
apy is required. Imaging techniques provide a non-invasive
method to determine treatment response and therefore can be
used as treatment follow-up of IFIs. Anatomical imaging, par-
ticularly with (chest and abdominal) computed tomography
(CT) but also with brain magnetic resonance imaging (MRI),
is usually used for the management of IFIs [4, 6]. However,
the anatomical changes associated with IFIs may persist for
long periods, even after adequate treatment, thereby potential-
ly delaying any further therapy that may be required for the
underlying disease [2]. Functional imaging with 2-
fluorodeoxyglucose positron emission tomography integrated
with CT (FDG-PET/CT) has been found useful in the moni-
toring of IFIs in a relatively small numbers of studies and case
reports available on this topic [2].
FDG-PET/CT has been used to monitor treatment in main-
ly oncological diseases but more recently also in infectious
diseases [7]. In monitoring disease, FDG-PET/CT has the ad-
vantage of using metabolic indices which provide absolute
quantification of the disease [8]. The metabolic indices have
also been shown to have prognostic value in different diseases
[9, 10]. Most widely used is the maximum standardized up-
take value (SUVmax). Other indices include the mean stan-
dardized uptake value (SUVmean), peak standardized uptake
value (SUVpeak), metabolic volume (MV) and total lesion
glycolysis (TLG). Each of these parameters has its advantages
and limitations, and there is no real agreement which is the
best parameter to use. SUVmean, MV, and TLG utilize the
uptake from the whole lesion rather than the highest voxel for
SUVmax or the highest uptake in a 1-ml volume (SUVpeak),
and may be more representative of disease burden in the le-
sion. TLG andMVhave been evaluated in oncology andmore
recently in inflammatory processes [9–12]. TLG was found to
be reproducible and highly correlated with other PET metrics
in the assessment of the response of treatment [8]. To the best
of our knowledge, metabolic parameters such as TLG andMV
have not been investigated in infections.
In this study, we (1) examine the role of serial FDG-PET/
CT in monitoring IFIs for therapy decision-making, and (2)
evaluate the role of the baseline metabolic parameters in
predicting the metabolic response to antifungal treatment.
Material and methods
We retrospectively assessed the electronic dossiers of patients
with definite or suspected IFIs who had more than one FDG-
PET/CT. The requirement for informed consent for this retro-
spective study was waived by the local institutional review
board (UMCG research register number 201600073).
Baseline FDG-PET/CTwas defined as an FDG-PET/CT per-
formed before or within 2 weeks of the initiation of antifungal
therapy. Patients with a definite diagnosis of IFI had fungi
cultured at the beginning or during the course of their treat-
ment. Patients who were diagnosed as clinical IFI had a clin-
ical suspicion of IFI with or without positive serological
markers for IFIs, and showed improvement on antifungal
treatment and clinical follow-up. For treatment evaluation,
FDG-PET/CTwas only performed when the treating clinician
felt the need to evaluate the IFI with imaging. We included
patients who had at least two FDG-PET/CT scans (one at
baseline, and one or more during treatment). In each patient
included in the study, two or more FDG-PET/CT scans at
different time points (one at baseline, and one or more during
treatment) were performed. The study was conducted at the
University Medical Center Groningen, the Netherlands, and
the period covered was from October 2009 until March 2018.
This time period was chosen since in October 2009 a PET/CT
camera system was installed at our center. Patients with no
baseline FDG-PET/CT scan, more than 2 weeks interruption
of their antifungal therapy between the serial FDG-PET/CT
scans, and no lesion on their baseline scans, such as those with
only blood-borne IFIs with no tissue localization, were
excluded.
Review of medical records
The following data were retrieved from the electronical patient
files: (1) the microbiology (serology, microscopy, and culture)
and pathology (biopsy or surgical excised lesion) that resulted
in the identification of IFI, (2) any other imaging that was
performed within 2 weeks of each FDG-PET/CT, (3) any pro-
cedure that was performed as a result of the FDG-PET/CT
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scan, (4) start date and duration of antifungal therapy, (5)
changes in treatment, (6) whether the patient was dead or alive
at the time of data collection, and (7) date and cause of death
were documented. We also reviewed the computer-based pa-
tient dossiers to determine what decision had beenmade based
on the FDG-PET/CT scan results.
FDG-PET/CT acquisition for IFIs
All scans were performed according to the EANM procedure
guideline for FDG-PET/CT studies [13]. Patients fasted for at
least 6 h before the study. The blood glucose was checked to
be less than 11 mmol/l before the injection of 3 MBq/kg 18F-
FDG. PET images were acquired on a research 4 Life
(EARL)-accredited integrated PET/CT camera system
(Biograph mCT 64 slice PET/CT, Siemens, Knoxville, TN,
USA) approximately 1 h after injection of the FDG. Patients
were imaged from mid-thigh to vertex of the skull with 3 min
per bed position. Low-dose CTwas performed for attenuation
correction and anatomical localization with the following set-
tings: tube voltage reference 100 kV (adjusted to 80–140Kv as
per departmental protocol) with Siemens CarekV switched on,
gantry rotation time of 0.5 s, pitch factor of 1, automated
exposure control switched on during all acquisitions
(Siemens CARE Dose4D), with a quality reference tube-
current product of 30mAs (adjusted to 20–50mAs as per de-
partmental protocol). CT images were not enhanced with
contrast.
Analysis of FDG-PET/CT scans
Images were interpreted by experienced nuclear medicine phy-
sicians as part of routine clinical care, using Syngo.Via software
(Siemens Healthcare, Erlangen Germany). Each scan was re-
evaluated by a nuclear physician (AA) who was blinded to the
original FDG-PET/CT interpretations. The parameters TLG,
MV, SUVmax, and SUVpeak were pre-defined in the
Syngo.Via software. For each FDG-PET/CT study, lesions
due to IFI were identified, the number of lesions were counted,
and volume of interests (VOIs) were drawn around the lesions.
IFI lesions were defined as abnormal focal lesions with or with-
out hypometabolic center not related to any procedure or other
existing pathology. TLG, MV, SUVmax, and SUVpeak was
recorded for every lesion due to IFI for each FDG-PET/CT
study. The findings of this second reading by the blinded nu-
clear physician (AA) were compared to the original FDG-PET/
CT reports and any discrepancies were resolved by an indepen-
dent nuclear physician (AWJMG).
Analysis of metabolic parameters
The TLG of the individual IFI lesions were summed for each
scan to calculate the global TLG for every FDG-PET/CT
study. The global MVof the IFI on each scan was also deter-
mined by the summation of the MVof the individual lesions.
The overall SUVmean of the lFI lesions was calculated by
dividing the global TLG by the global MV. The highest
SUVmax and SUVpeak for each study were also recorded.
SUVmax, SUVpeak, and TLG were corrected for glucose
by the formula (parameter × 5/blood glucose in mmol/l) ac-
cording to the EANM standards.
Definitions of metabolic response and altered
treatment
The responses of IFIs to treatment were classified into three
groups based on FDG-PET/CT findings on the final study: (1)
patients with a complete metabolic response (CMR), (2) with
a partial response, and (3) patients with progression of the
infection. CMR was defined as a complete resolution of the
FDG uptake due to IFI compared to the background at the site
of IFI. A partial response was defined as any reduction in FDG
uptake not reaching complete normalisation. Progression of
the infection was defined as the appearance of new lesions
or an increase in the size or intensity of existing lesions due
to IFIs. When FDG-PET/CT led to a cessation or change in
antifungal drugs or resulted in surgery, it was defined as alter-
ation of the therapy and having added value. If FDG-PET/CT
led to a prolongation of therapy (because of partial response) it
was considered as having added value.
Statistical analysis
Descriptive statistics (mean and standard deviation or mode
and range) was used to describe patient and scan data. Data
was tested statistically using SPSS Version 23 (IBM Inc.,
Armonk, NY). Receiver operator characteristic (ROC) analy-
sis was performed to determine whether the metabolic param-
eters would be able to discriminate patients who had a com-
plete metabolic response (CMR) on their final scan from those
who did not have a CMR. Independent t-test was used to
determine differences in means, and Fisher’s Exact test was
used for the difference of categorical values. P-values of less
than 0.05 were considered significant.
Results
Demographic and diagnosis of IFIs and underlying
disease
In total, we found 44 patients with IFIs who hadmore than one
FDG-PET/CT. After screening, 28 patients were included. Of
the 16 patients that were excluded, eight had no baseline
scans, five had their antifungal therapy interrupted by more
than 2 weeks in between the serial scans, and in three the
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baseline scan did not show any FDG-avid lesion (blood-borne
IFI in two, and intracerebral candidiasis with no other lesion in
one). The demographics of the included patients, type of fun-
gi, diagnosis made, and underlying disease are displayed in
Table 1. Seventeen of our patients (61%) were males. The
mean age of the patients at the time of their baseline FDG-
PET/CT scan was 43 ± 22 years. The diagnosis of IFIs was
proven by isolation and growth of fungi in 18 (64%). In the
others, diagnosis was made clinically. The majority of patients
(n = 19, 68%) had a hematologic disorder underlying the IFI.
Solid organ transplant was present in six (21%) of the patients.
The median duration of treatment from the start of antifungal
treatment to the date of the last FDG-PET/CT performed was
33.5 weeks (range 5–242).
FDG PET/CT findings
The findings from the FDG-PET/CT studies are summarized
in Table 2. A total of 98 PET/CTstudies from 28 patients were
analysed. The median number of scans per patient was 3
(range, 2–9).
Patients with a complete metabolic response
Nineteen (68%) of the 28 patients showed a CMR at the last
FDG-PET/CT scan. In eight of the patients with CMR, FDG-
PET/CT led to a cessation of therapy. Figure 1 shows the
FDG-PET images of a patient who had a CMR at final scan.
In four of the 19 patients (21%), a heterogeneous response to
the antifungal therapy was found, with some lesions
responding to antifungal therapy but also new lesions
appearing.
Patients with an incomplete response (partial response
and progressive disease)
In total, nine patients did not achieve a CMR at the last
FDG-PET/CT study. An overview of the results of these
patients is shown in Table 3. Two of these patients
showed progressive disease, and seven had a partial re-
sponse at the last FDG-PET/CT study. Two of the patients
with a partial response had a complex pulmonary lesion
with no other site of IFI at the last FDG-PET/CT scan.
Both of the patients had a video-assisted thoracic resec-
tion and subsequently underwent autologous stem-cell
transplantation. In one of these, the resected tissue did
not show any fungal elements, while the second one had
fungal elements. The median percentage change in TLG
in all the nine patients with a partial response was −80%,
ranging from −43% to −90%. Seven out of the patients
who did not achieve CMR had aspergillosis and two had
candidiasis. Six out of the seven patients with aspergillo-
sis that did not have a CMR response on their last FDG-
PET/CT study had residual pulmonary lesions, with most
of these lesions being complex with an irregular metabolic
uptake. Figure 2 shows the FDG-PET MIP images of a
patient with aspergillosis and a residual pulmonary lesion.
The two cases due to candidiasis occurred in regions with
high FDG signal (brain and kidneys), and were eventually
followed up with other anatomically based methods.




Female sex: n (%) 11 (39%)
Age in years (mean ± SD) 43 ± 22
Type of IFI (n)
Aspergillosis 18 (64%)
– Aspergillus fumigatus 8
– Aspergillus nidus 1
– Aspergillus ustus 1
– Aspergillosis (species not specified) 8
Candida 9 (32%)
– Candida albicans 5
– Candida glabatara 1
– Candida dubliniensis 1
– Candidiasis (unspecified species) 2
Other 1 (4%)
– Hormografiella aspergillata 1
Final diagnosis of IFI (n)
Proven 18 (64%)
Clinical 10 (36%)
Risk factor or underlying disorder for IFI (n)
Hematological malignancy or disorder 19 (68%)
– Acute myeloid leukemia 8
– Acute lymphoblastic leukemia 5
– Hematopoietic stem cell transplant 1
– Non-Hodgkin’s lymphoma 3
– Chronic lymphocytic lymphoma 1
– Langerhans cell histiocytosis 1
Solid organ transplant 6 (21%)
– Kidney 1
– Lung 3
– Heart and lung 2
Immunosuppression unrelated malignancy 2 (7%)
– Panniculitis 1
– Rheumatoid arthritis 1
Other 1 (3%)
– Autosomal dominant polycystic kidney disease 1
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Therapy decision-making based on FDG-PET/CT
results
Prolongation of therapy
FDG-PET/CT resulted in a prolongation in therapy in 18 pa-
tients (64%). In these patients, there was still evidence of
metabolic activity at the site of the original IFI lesions at a
time when patients were clinically stable. This resulted in the
prolongation of antifungal therapy. At a later scan, four of
these patients also had their therapy altered, and in two pa-
tients therapy was stopped. Figure 1 shows four FDG-PET
MIP images of a patient that led to both a prolongation and
a change of the antifungal therapy.
Change in therapy
FDG-PET/CT resulted in a change in therapy in eight patients.
The changes in the metabolic parameters over time in one of
these patients (the same patient as in Fig. 1), is illustrated in
Table 4. The metabolic changes and data for all the eight
patients in whom FDG-PET/CT led to a therapy change is
available as supplementary material. The global TLG provid-
ed information about extent and severity of disease which
corresponded to reports. The other metabolic parameters, es-
pecially the highest SUVmax, SUVpeak, and SUVmean, se-
verely underestimated (or overestimated) the changes in IFI
burden determined by TLG (Table 4 and supplementary
material).
Added value of PET/CT and alteration
In total, FDG-PET/CT added value to treatment in 26
(93%) of our patients. In 12 it led to a prolongation of
therapy only; in six other patients in whom it led to a
prolongation, it also led to either a cessation in therapy
or change of therapy. In eight patients, it led to a change
in antifungal drugs; four of these also had their therapy
prolonged at a later FDG-PET/CT scan. In eight it led to
cessation of therapy; two of these also had their antifungal
drugs changed, leaving six patients who had a cessation in
therapy alone (Table 2). FDG-PET/CT altered the man-
agement of antifungal treatment (stopped therapy or led
to a change) in 14 (50%) of the patients.
Table 2 Findings of FDG-PET/
CT, therapy outcome and change
in therapy by fungi, and response
outcome on the final study
FDG-PET/CT scans
Total number reviewed 98
Number of scans per patient: median (range) 3 (2–9)
Duration of therapy till the last PET/CT scan
in weeks: median (range)
33.5 (5–242)
Finding on final FDG-PET/CT scan of patients (n)
Complete metabolic response (CMR) 19 (68%)
Partial response (PR) 7 (25%)
Progressive disease (PD) 2 (7%)
Total 28
FDG-PET/CT leading to a change in antifungal
Fungi type (n)
Aspergillosis 6 (33% of patients with aspergillosis)
Candidiasis 1 (11% of patients with candidiasis)
Hormografiella aspergillata 1
Total 8 (29% of all patients)
FDG-PET/CT leading to prolongation of therapy
Fungi type (n)
Mold 10 (52.6% of pts. with mold)
Yeast 8 (89% of pts. with yeast)
Total 18 (64% of all patients); in four also led
to a change, in two also led to stopping
of the antifungal
FDG-PET/CT added value
Change 8 (29% of the total)
Stopped therapy only 6 (21% of total)
Prolongation only 12 (43% of total)
Total 26 (93% of the total patients)
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Outcome after last PET/CT Comment
6 2/F 15 6 42 Cana AMLb − 44 Therapy prolonged but
subsequent follow up with
MRI
Brain lesions not distinct on PET/CT,
partial response in spleen and kidneys
7 65/M 1 2 26 Aspc AML − 86 Patient had video-assisted
thoracic surgery and FDG
avid lesions resected
ASCTd successful with no complication
9 53/F 1 3 13 Can ADPKDe − 75 Therapy prolonged but
subsequent follow up was
by clinical parameters
Infected renal cyst, FDG tracer excretion
interfered with follow-up by PET/CT
14 3/F 8 3 105 Asp LCHf + 25 Therapy changed, but the
patient died 14 weeks later
Death due to IFI complications
15 62/M 3 2 23 Asp NHLg − 80 Treatment prolonged but died Death due to due to recurrent NHL which
could not be treated due to the poor
condition of the patient
17 66/M 3 8 43 Asp AML − 90 Treatment prolonged but died
after 4 weeks
Death related to IFI complication
22 62/M 1 2 13 Asp ALLh + 50 Therapy changed: patient died
3 weeks later
Death due to bacterial complications
24 25/F 2 3 22 Asp ALL − 62 Still on therapy as time of data
collection
Therapy prolonged due to PET/CT
28 65/M 5 3 10 Asp AML − 69 Patient had video-assisted
thoracic surgery and FDG
avid lesions resected
ASCT successfully done with no
complication
a Can— Candida sp.
b AML— acute myeloid leukemia
c Asp— Aspergillus sp.
d ASCT— allogeneic stem cell transplantation
e ADPKD— autosomal dominant polycystic kidney disease
f LCH— Langerhans cell histiocytosis
g Non-Hodgkin’s lymphoma
hALL— Acute lymphoblastic leukemia
Fig. 1 FDG-PET MIP images of
a 38-year-old male with acute
lymphoblastic leukemia (ALL)
who was first thought to have a
bacterial infection but was
unresponsive to antibiotics. A
clinical diagnosis of invasive
candidiasis was made, at baseline
FDG-PET/CT a global TLG of
401. Follow-up FDG-PET/CT
showed a good response with a
TLG of 30. Then the patient
developed fever, with negative
blood cultures, and a repeated
FDG-PET/CT showed new
lesions with a global TLG of 900.
The antifungal therapy was
modified, and the patient had a
complete metabolic response at
the last scan
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Mortality
Seven of the patients (25%) had died at the time of the anal-
ysis. Three of the deaths were in patients who had a CMR to
therapy and four in patients with an incomplete response to
treatment. The patients with CMR all diedmore than 6months
after the last PET/CT, while the deaths in patients who did not
achieve a CMR occurred within 4 months. The deaths in pa-
tients who had CMR occurred at 26, 29, and 30 weeks after
the last FDG-PET/CT scan; the cause of death was bacterial
complications in all these patients. Three of the deaths were
due to the IFI, and all occurred in the patients with an incom-
plete metabolic response. These deaths occurred at 3, 4, and
13 weeks after the last FDG-PET/CT scan. The last patient
who died in the group who did not get a CMR died of recur-
rent non-Hodgkin’s lymphoma; this patient died 9 weeks after
FDG-PET/CT. The difference in overall mortality was not
significant (p = 0.165) but was significant for mortality due
to IFI (p = 0.026) using Fisher’s Exact test analysis.
Differences between baseline FDG-PET/CT findings
in CMR and non-responders
A significant difference was found between the average
number of lesions for the CMR group and those who did
not have a complete response at the final FDG-PET/CT
(20.7 vs 4.33, p = 0.007). Using receiver operating
acharacteristic (ROC) analysis, we found that baseline
TLG and MV were able to discriminate between patients
eventually having a CMR and patients who did not achieve
CMR (Table 4). Baseline TLG had the highest area under
the curve (AUC) of 0.95, and discriminated CMR from
non-responders at a cut-off of 160 with a sensitivity of
94% and specificity of 100% (Table 5). None of the base-
line metabolic parameters (TLG, MV, SUVmax, SUVpeak,
and SUVmean) was able to discriminate between patients
who eventually needed prolongation of therapy and pa-
tients who required a change in treatment based on FDG-
PET/CT findings.
Fig. 2 FDG-PET MIP images of a 65-year-old male with AML and
diagnosed with aspergillosis from the culture of bronchoalveolar lavage
washing (Aspergillus fumigatus). Note the complex large heterogeneous
pulmonary lesion which did respond but not completely disappear at the
final FDG-PET/CT. The patient had a baseline TLG of 144 of the
pulmonary lesions. The follow-up scan shows a heterogeneous
response, with resolution of the lesions in the right lower lobe below
the primary lesion but with appearance of new lesions in the left lung
and global TLG of 187. Antifungal therapy was modified, and the last
scan showed resolution of lesions except for the primary aspergillus
lesion with TLG of 44 after 6 months. This patient had a video-assisted
resection of the lesion and subsequently had allogeneic stem cell
transplantation (ASCT)
Table 4 Metabolic parameters
and the % change from the
previous FDG-PET/CT study of
patient whose MIP images are
demonstrated in Fig. 1
1st scan 2nd scan 3rd scan (therapy changed) 4th scan
Global TLG 401.14 29.98 (− 93%) 900.44 (+ 2903%) No lesion
Global MV 197.61 13.5 (− 93%) 407.44 (+ 2918%) No lesion
Global SUVmean 2.03 2.22 (+ 9%) 2.21 (0%) No lesion
Highest SUVmax 7.14 6.43 (− 10%) 18.75 (+ 192%) No lesion
Highest SUVpeak 4.47 4.61 (+ 3%) 12.35 (+ 168%) No lesion
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Discussion
IFI is a life-threatening condition, and only scarce data are
available with regard to imaging. Our study provides im-
portant data on the role of FDG-PET/CT in monitoring
IFIs. Of particular importance is the ability of TLG to pro-
vide quantification of the burden of disease due to IFI, the
ability of the baseline TLG to predict patients who will
achieve a CMR when patients are treated with antifungal
drugs, and the fact that FDG-PET/CT has added value in
therapy decision-making in a large proportion of the
patients.
Our study is the first study to evaluate the role of TLG
and MV in infectious diseases. We found TLG was able to
provide a quantitative measurement of IFI burden, which
correlates well with the reports which were based on visual
analysis. TLG and MV were found to be able to predict
whether a patient will achieve CMR. This was not the case
for the SUVmax, SUVpeak, and SUVmean. This finding
indirectly supports the idea that either TLG or MV may be
a better parameter to use when comparing scans of patients
with systemic diseases such as IFIs compared to SUV pa-
rameters. The global TLG at baseline may be used to pre-
dict patients who will not completely respond to an anti-
fungal agent and will have persistent FDG uptake or will
require surgical resection of IFI lesion. This distinction is
essential to avoid unnecessary delay in instituting further
therapies such as allogeneic stem cell transplantation
(ASCT) based on when FDG-PET/CT is used for monitor-
ing IFIs. While a CMR is achievable in the majority of
cases, in some patients this may not always be possible.
This may result in unnecessary prolongation of antifungal
therapy, wi th associa ted s ide-effec ts and costs .
Furthermore, it may delay further necessary intervention
such as ASCT if the monitoring was based on FDG-PET/
CT only in these patients. This persistent FDG activity in
IFIs has been documented by other authors [14], and has
also been reported in other nonfungal infections after pa-
tients have been cured of infection [15]. The persistent
uptake may be related to old lesions such as fibrosis that
the body is trying to eradicate by activated immune cells
such as macrophages, giant cells, and lymphocytes with
FDG uptake not due to active IFI.
Our findings on the added value of FDG-PET/CT in
therapy decision-making in patients with IFIs are in sup-
port with other studies that demonstrated the value of
FDG-PET/CT in monitoring treatment of IFIs. In one
study, FDG-PET/CT was compared to conventional CT in
detecting and guiding management of IFIs. This study
found 94% (30/32) of the FDG-PET/CT scans to be useful
in evaluating therapy response [16]. In another study,
FDG-PET/CT was found to lead to altered treatment by
stopping or reducing the dose in 15% (8/54) or changing
or increasing the dose of antifungal drugs in 31% (17/54)
cases [17]. IFI is a rare disease, and a large multi-centre
study will be necessary to validate our findings.
In patients with underlying hematologic malignancies
who develop IFI after neutropenia, antifungal therapy is
usually necessary for an extensive period of time (months
to even years) as the immune system of the host is not
effective in clearing the organism. If the treatment of the
underlying condition of the IFI involves further depression
of the immune system such as ASCT, there is the risk of
dissemination of IFI during treatment. Monitoring is cru-
cial to treat IFIs adequately, but also not to subject the
patients to unnecessary treatment with toxic effects and to
lower the expensive costs of the treatment [2]. In our study,
the mean duration of treatment till the last FDG-PET/CT
was 33.5 weeks (range, 5–242). International organizations
such as the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID), the Infectious Diseases
Soc ie ty of Amer ica ( IDSA) , and the European
Conference on Infection in Leukaemia recommend a
search for disseminated infection in a leukemic patient
with an IFI recovering from neutropenia [18]. The methods
they recommended for excluding a disseminated IFI in-
cluded transoesophageal echocardiography, funduscopic
evaluation, and/or abdominal imaging. These methods are
region- or organ-specific, and are not able to detect occult
IFIs at other sites concurrently. FDG-PET/CT as a whole
body tool is able to evaluate several sites in one study.
Organs in the body that have a high metabolic signal
may limit the role of FDG-PET/CT as a monitoring tool
[4]. FDG-PET/CT monitoring of IFIs was not optimal in
patients with predominantly cerebral and renal lesions in
our study. The advantages and disadvantages of the various
Table 5 ROC analysis of initial
or baseline metabolic parameters
and response to therapy
Parameter AUCa P value Best cut-off Sensitivity (%) Specificity (%)
TLG 0.954 < 0.001 160 94 100
MV 0.908 0.001 60 84 75
SUVmax 0.629 0.269 5.47 82 50
SUVpeak 0.576 0.514 4.42 82 40
SUVmean 0.588 0.426 2.35 76 50
aAUC— area under the curve
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imaging tools must be appreciated by the clinician, and the
most appropriate utilized for the best patient outcome.
The serial FDG-PET/CT scans for IFI monitoring were
acquired at different time points during the treatment. This
is because the patients with IFIs have different underlying
risk factors with different degrees of immune suppression.
Furthermore, the genus and species of fungi causing IFIs
are also different, making it difficult to perform FDG-PET/
CT at a fixed point in time. The timing of the follow-up
scan should be dictated by the clinical condition of the
patient, allowing personalized therapy decisions of this
life-threatening infection.
The mortality in our patients directly due to IFIs was
11%, and the overall mortality was 25%. All the patients
who died due to IFIs were patients who did not have a
CMR at the last scan. The mortality of 11% of IFI patients
who were on treatment underscores the importance of de-
veloping new strategies for the management of IFIs. New
strategies including vaccine, cytokiness, and cellular im-
munotherapy have been investigated at a preclinical level
[19]. FDG-PET/CT is well positioned to provide quantita-
tive assessment of the burden of IFI in patients when these
therapeutic interventions are translated to humans.
Furthermore, the lack of statistical significance between
the mortality of the CMR group and non-CMR group, but
the significant difference when mortality due to IFI is con-
sidered, may suggest a prognostic role of metabolic re-
sponse on the last study. However, our sample size is too
small to fully explore this. Larger multicentre prospective
studies are needed to confirm the prognostic value of FDG-
PET/CT study in monitoring IFIs.
Our study has some limitations regarding the small sam-
ple size, the retrospective nature of our study, and data
coming from a single center, which may limit its general-
ization. Our strict inclusion criteria may have systematical-
ly excluded very ill patients who were unable to undergo
several FDG-PET/CT scans. In some of our patients the
IFIs were not proven by biopsy, but this is in our opinion
the clinical practice; it is not always possible to have full
proof by biopsies.
Conclusion
FDG-PET/CT is useful for therapy monitoring in patients with
IFIs, and helps in therapy decision-making, resulting in alter-
ation of treatment strategy in 50% of patients. TLG andMVat
baseline scan were found to be useful predictors of metabolic
response to antifungal therapy. Since IFIs are uncommon,
prospective multicentre trials in homogenous patient popula-
tions are necessary to confirm these findings. Eventually,
FDG-PET/CT may be added to the diagnostic and therapeutic
flowcharts of patients with IFI.
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